J
Joseph L. Duffy
Researcher at Merck & Co.
Publications - 91
Citations - 2168
Joseph L. Duffy is an academic researcher from Merck & Co.. The author has contributed to research in topics: Aldol reaction & Neuropathic pain. The author has an hindex of 22, co-authored 91 publications receiving 1950 citations. Previous affiliations of Joseph L. Duffy include Harvard University.
Papers
More filters
Journal ArticleDOI
A Stereochemical Model for Merged 1,2- and 1,3-Asymmetric Induction in Diastereoselective Mukaiyama Aldol Addition Reactions and Related Processes
TL;DR: In this article, the authors investigated the direction and degree of stereoselectivity in aldol addition reactions involving achiral unsubstituted metal enolate and enolsilane nucleophiles and chiral aldehydes.
Journal ArticleDOI
Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice
Nicholas B. Hastings,Xiaohai Wang,Lixin Song,Brent D. Butts,Diane Grotz,Richard Hargreaves,J. Fred Hess,Kwok-Lam Karen Hong,Cathy Ruey-Ruey Huang,Lynn A. Hyde,Maureen Laverty,Julie Lee,Diane Levitan,Sherry X. Lu,Maureen Maguire,Veeravan Mahadomrongkul,Ernest J. McEachern,Xuesong Ouyang,Thomas W. Rosahl,Harold G. Selnick,Michaela C. Stanton,Giuseppe Terracina,David J. Vocadlo,Ganfeng Wang,Joseph L. Duffy,Eric M. Parker,Lili Zhang +26 more
TL;DR: It is demonstrated that chronic inhibition of OGA reduces pathological t Tau in the brain and total tau in the CSF of rTg4510 mice, most likely by directly increasing O-GlcNAcylation of tau and thereby maintaining tauIn the soluble, non-toxic form by reducing tau aggregation and the accompanying panoply of deleterious post-translational modifications.
Patent
Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
TL;DR: In this article, the authors proposed phenylalanine derivatives which are inhibitors of the dipeptidyl peptidyl enzyme-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the PD enzyme is involved.
Journal ArticleDOI
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Sajjad A. Qureshi,Mari R. Candelore,Dan Xie,Xiaodong Yang,Laurie Tota,Victor D.-H. Ding,Zhihua Li,Alka Bansal,Corin O. Miller,Sheila M. Cohen,Guoqiang Jiang,Ed Brady,Richard Saperstein,Joseph L. Duffy,James R. Tata,Kevin T. Chapman,David E. Moller,Bei B. Zhang +17 more
TL;DR: Compound 1 (Cpd 1) is a potent glucagon receptor antagonist that has the capability to block the effects of glucagon in vivo, and real-time measurement of glycogen synthesis and breakdown in perfused mouse liver showed that Cpd 1 is capable of blocking glucagon-induced glycogenolysis in a dosage-dependent manner.
Journal ArticleDOI
1,3-Asymmetric induction in the aldol addition reactions of methyl ketone enolates and enolsilanes to β-substituted aldehydes. A model for chirality transfer
TL;DR: In this article, a model for 1,3-asymmetric induction for polar addition processes such as the Mukaiyama aldol reaction is proposed to account for the documented trends in reaction diastereoselection for polar β-substituents.